GLYCOSYLATED SPECIFICITY EXCHANGER
The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
1 . An isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to a blood group antigen.
2 . The isolated glycoconjugate peptide of claim 1 , wherein said glycoconjugate peptide is linear.
3 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is blood group antigen A.
4 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is blood group antigen B.
5 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is blood group antigen RhD.
6 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is synthetically conjugated to said HIV gp120 binding fragment of CD4 by attachment at one amino acid.
7 . The isolated glycoconjugate peptide of claim 6 , wherein said blood group antigen is synthetically conjugated to a hydroxylated amino acid.
8 . The isolated glycoconjugate peptide of claim 6 , wherein said blood group antigen is synthetically conjugated by an NH 2 -linkage.
9 . The isolated glycoconjugate peptide of claim 6 , wherein said blood group antigen is synthetically conjugated to the N-terminal end of HIV gp120 binding fragment of CD4.
10 . The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 200 amino acids in length.
11 . The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 150 amino acids in length.
12 . The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 100 amino acids in length.
13 . The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 50 amino acids in length.
14 . The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than 25 amino acids in length.
15 . The isolated glycoconjugate peptide of claim 1 , wherein said HIV gp120 binding fragment of CD4 is less than or equal to 15 amino acids in length.
16 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is synthetically conjugated to a hydroxylated amino acid.
17 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is synthetically conjugated by an NH 2 -linkage.
18 . The isolated glycoconjugate peptide of claim 1 , wherein said blood group antigen is synthetically conjugated to the N-terminal end of said HIV gp120 binding fragment of CD4.
19 . A method of ameliorating HIV proliferation in a subject comprising:
identifying a subject infected with HIV; and
providing an isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to a blood group antigen to said subject.
20 . A method of ameliorating HIV proliferation in a subject comprising:
identifying a subject infected with HIV; and
providing an isolated glycoconjugate peptide comprising an HIV gp120 binding fragment of CD4 synthetically conjugated to gal a (1,3) gal β to said subject.